What issurvodutidepeptide used for Mazdutide is a novel peptide therapeutic that has emerged as a promising agent for weight management and the treatment of type 2 diabetes (T2D). This long-acting, once-weekly injectable medicine functions as a dual agonist, targeting both the GLP-1 (glucagon-like peptide-1) receptor and the glucagon receptor (GCGR). By simultaneously activating these receptors, mazdutide offers a unique mechanism that aims to enhance weight loss efficacy and improve metabolic health作者：L Guo·2025—Mazdutide is a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonistdeveloped for the treatment of type 2 diabetes (T2D) 1 .... Its primary applications are in aiding chronic weight management in adults with obesity or overweight, and in managing blood glucose levels for individuals with type 2 diabetes.
As a dual agonist, mazdutide leverages the combined effects of GLP-1 and glucagon pathways.2022年10月21日—“The results of the higher-dosemazdutidemake it the first single-agent anti-obesity drug worldwide to achieve a 12-week body weight loss by ... GLP-1 receptor agonists are well-established for their roles in stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety, all of which contribute to reduced food intake and subsequent body weight loss. The addition of glucagon receptor agonism is thought to further enhance metabolic benefits, potentially by increasing energy expenditure and improving hepatic metabolic function. This dual action is believed to be key to mazdutide's observed effectiveness in clinical studies, showing significant reductions in body weight and improvements in cardiometabolic risk factorsMazdutide (also known as IBI362 or LY3305677)is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM)..
The primary use of mazdutide is in the treatment of obesity and overweight individuals. Clinical trials have demonstrated substantial body weight loss with mazdutide treatment, with some studies reporting significant percentage reductions in body weight and waist circumference. Beyond weight management, mazdutide is also indicated for individuals with type 2 diabetes. Studies have shown that it can improve glycemic control, evidenced by reductions in HbA1c levelsTherapeutic: mazdutide for obesity.
Emerging research also suggests potential benefits for other metabolic and inflammatory diseases. Mazdutide is being investigated for its role in mitigating cognitive deficits associated with metabolic disorders and for treating non-alcoholic fatty liver disease (NAFLD)作者：SN Bhattachar·2025·被引用次数：1—Mazdutide is a novel agonist of GLP-1 and glucagon receptors under clinical development forchronic weight management. It is administered once .... Its ability to improve hepatic metabolic function, reduce triglycerides, and modulate lipid profiles further underscores its potential as a comprehensive therapeutic agent for a range of metabolic conditions.
Mazdutide is often discussed alongside other weight loss peptides such as semaglutide and tirzepatide.2025年10月31日—With successive approvals forweight management and T2D indications, we believe mazdutide will benefit a wide range of patients requiring ... Head-to-head comparisons have indicated that mazdutide may show superiority to semaglutide in terms of weight loss efficacy. While tirzepatide is also a dual GIP/GLP-1 receptor agonist, mazdutide's dual GLP-1/glucagon agonism represents a distinct approach. These comparisons highlight the ongoing advancements in peptide therapeutics for metabolic diseases, offering patients and clinicians a growing array of options tailored to specific needs and desired outcomes.Retatrutide: the Newest Weight Loss Peptide
Mazdutide is administered as a once-weekly injection, making it a convenient option for long-term treatment. Like other GLP-1 receptor agonists, common side effects tend to be gastrointestinal in nature, such as nausea, diarrhea, and constipation. However, clinical studies have generally found mazdutide to be safe and well-tolerated, particularly at effective doses for weight management and glycemic control. Ongoing research continues to assess its long-term safety profile and potential adverse events across various patient populations.
Mazdutide represents a significant development in the field of metabolic disease treatment.(PDF) A phase 2 randomised controlled trial of mazdutide ... Its dual-acting mechanism offers a powerful tool for tackling obesity and type 2 diabetes, with expanding potential applications in related conditions like NAFLDInnovent Announces Mazdutide, First Dual GCG/GLP-1 .... As research progresses and clinical data matures, mazdutide is poised to become an important therapeutic option for individuals seeking effective weight management and improved metabolic health.
Join the newsletter to receive news, updates, new products and freebies in your inbox.